$-0.17 EPS Expected for Cempra Inc (CEMP)

October 12, 2017 - By Winifred Garcia


Investors sentiment increased to 0.91 in Q2 2017. Its up 0.08, from 0.83 in 2017Q1. It increased, as 12 investors sold Cempra Inc shares while 32 reduced holdings. 14 funds opened positions while 26 raised stakes. 25.76 million shares or 1.24% more from 25.44 million shares in 2017Q1 were reported.
Palo Alto Invsts Ltd accumulated 0.07% or 340,320 shares. Bnp Paribas Arbitrage, a New York-based fund reported 5,055 shares. Products Partners Limited Liability, a New York-based fund reported 472,200 shares. Lmr Prtnrs Limited Liability Partnership invested in 32,584 shares or 0.01% of the stock. Dimensional Fund Advsr L P has 0% invested in Cempra Inc (NASDAQ:CEMP) for 753,402 shares. 440 were accumulated by Meeder Asset Mngmt Incorporated. Susquehanna Intll Gp Llp reported 174,440 shares. Gabelli Funds Llc stated it has 0.01% of its portfolio in Cempra Inc (NASDAQ:CEMP). Ameriprise Incorporated owns 35,525 shares or 0% of their US portfolio. State Board Of Administration Of Florida Retirement holds 0% or 18,843 shares in its portfolio. The New York-based Bancorporation Of New York Mellon Corp has invested 0% in Cempra Inc (NASDAQ:CEMP). Sg Americas Securities Lc holds 0% of its portfolio in Cempra Inc (NASDAQ:CEMP) for 10,019 shares. The New York-based Levin Capital Strategies Ltd Partnership has invested 0% in Cempra Inc (NASDAQ:CEMP). 12,813 are owned by Legal And General Public Limited Com. Northwestern Mutual Wealth Mngmt accumulated 0% or 2,289 shares.

Analysts expect Cempra Inc (NASDAQ:CEMP) to report $-0.17 EPS on October, 26.They anticipate $0.45 EPS change or 72.58 % from last quarter’s $-0.62 EPS. After having $-0.23 EPS previously, Cempra Inc’s analysts see -26.09 % EPS growth. About 464,838 shares traded. Cempra Inc (NASDAQ:CEMP) has declined 75.26% since October 12, 2016 and is downtrending. It has underperformed by 91.96% the S&P500.

Cempra Inc (NASDAQ:CEMP) Ratings Coverage

Among 16 analysts covering Cempra (NASDAQ:CEMP), 2 have Buy rating, 3 Sell and 11 Hold. Therefore 13% are positive. Cempra had 38 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Raymond James given on Tuesday, September 13. The rating was downgraded by Gabelli to “Sell” on Wednesday, March 29. The rating was upgraded by Morgan Stanley to “Equal-Weight” on Friday, December 30. The firm earned “Neutral” rating on Thursday, December 29 by Ladenburg Thalmann. Needham downgraded Cempra Inc (NASDAQ:CEMP) on Sunday, November 13 to “Hold” rating. The firm has “Neutral” rating by TH Capital given on Friday, December 30. The stock of Cempra Inc (NASDAQ:CEMP) earned “Buy” rating by Needham on Thursday, July 30. The stock of Cempra Inc (NASDAQ:CEMP) earned “Equal-Weight” rating by Morgan Stanley on Thursday, August 13. The firm has “Buy” rating by Stifel Nicolaus given on Friday, June 24. The stock has “Neutral” rating by JP Morgan on Thursday, November 3.

Cempra, Inc. is a clinical-stage pharmaceutical company. The company has market cap of $166.71 million. The Firm focuses on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases. It currently has negative earnings. The Company’s product, solithromycin , which is a macrolide and fluoroketolide, is being developed in oral capsules, intravenous (IV) and suspension formulations for the treatment of community-acquired bacterial pneumonia (CABP).

More news for Cempra Inc (NASDAQ:CEMP) were recently published by: Globenewswire.com, which released: “Cempra and Melinta Announce Expiration of Hart-Scott-Rodino Waiting Period for …” on September 28, 2017. Seekingalpha.com‘s article titled: “Cempra, Inc.: Our Take On FDA’s Question On Liver Enzyme Elevation Due To …” and published on November 02, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com